- Major pharmaceutical companies, including Pfizer, AstraZeneca, and Merck, announced several new partnerships and acquisitions in the oncology sector.
- Pfizer acquired Biohaven Pharmaceuticals, Seagen, and Arena Pharmaceuticals in transactions dating back to 2022.
Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
1 report, 1 independent
Updated Aug 26
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Financial analysts reviewed Biohaven's strategic asset sales and corporate strategy following its acquisition by Pfizer.
Who's involved
What this event is mainly aboutKeep exploring
The entities involved
-
Pfizer
American multinational pharmaceutical and biotechnology corporation
-
Leerink partners
U.S. investment bank
Related events
- MarketBeat is providing analyst ratings and tracking the competitive landscape between healthcare companies Pfizer and Lyra Therapeutics.
- Collaboration revenue realization from Pfizer and GSK backing royalty financing for Spero Therapeutics.
- Market growth is being driven by advanced therapies involving Pfizer, Novartis, and Merck.
- Pfizer, Johnson & Johnson, and Merck are facing significant industry pressures due to patent cliffs and market pricing demands.
- Bristol-Myers Squibb and Pfizer are co-marketing Eliquis, while both companies are noted as dividend payers.